Re-Vana Therapeutics - Queens University Belfast UK Spin Out

**Novel Technologies**
Two Photo crosslinked technologies
- Implant and In situ implant forming gel
- Sustained Release: Large and Small molecule drug delivery - 4 months or greater
- > 50% biologic drug loading

**Experienced Team**
- Extensive global, commercial and drug delivery development expertise

**Tolerability and PK Data**
Six-month in vivo study complete
- Sustained drug delivery projected delivery to 4 months or more with an anti-VEGF drug
- Outstanding tolerability out to six months in a challenging animal model

**Capital Raised**
- $1.6M Seed
- $2.0M Pre-Series A (Term sheet executed)
- $600K Innovate UK Grant
- One collaboration to date - additional strategic discussions in progress
Innovative Delivery Platforms and Therapeutic Opportunities

<table>
<thead>
<tr>
<th>EyeLief™</th>
<th>OcuLief™</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-formed photocrosslinked implant</td>
<td>In situ implant forming gel</td>
</tr>
<tr>
<td>Injected with a conventional applicator</td>
<td>Novel applicator with a built-in UV source</td>
</tr>
<tr>
<td>Tailored crosslinking ➔ tailored release profiles</td>
<td></td>
</tr>
<tr>
<td>Suitable for both small and large drug molecules</td>
<td></td>
</tr>
</tbody>
</table>
High loading (>50% w/w) of both Large and Small molecules has been achieved

Fabrication procedure avoids extreme pH conditions, elevated temperatures or use of organic solvents – reduces stability risks for biologics (activity of released biologic is >80%)

Tailored release profiles, biodegradable/biocompatible
OcuLief™ – Advancing Large and Small Drug Delivery

Gel-based depot delivery system

- Gel-based in situ depot forming photo-crosslinked delivery system
- High drug loading of biologics >30% w/w
- Low injectable volumes (20 - 50 µL) with higher release rates (e.g., 10-25 µg/day)
- Tailored release profiles & biodegradable/biocompatible

In vitro release of Bevacizumab (Approx. 6 months)

In vitro release of Triamcinolone Acetonide
6 Month Safety/Tolerability-PK Studies Bevacizumab w. EyeLief™

### Ocular Examinations

<table>
<thead>
<tr>
<th>Day 0 (Retinal baseline)</th>
<th>Day 7</th>
<th>Day 28</th>
<th>Month 3</th>
<th>Month 6</th>
</tr>
</thead>
</table>

**Implant structure maintained throughout the release period**

- Excellent Tolerability: No evidence of irritation or significant inflammatory response
- No increases in IOP values between Days 0, 7, 28 and month 3
- Maintained therapeutic concentrations, predicted sustained release for 4 months
- At 3 months, Bevacizumab concentrations in rabbits vitreous humor were approx. 7 times higher of the IC50 of BEZ, which is 0.67 nM (i.e., 0.1 µg/mL)

Re-Vana Strategy

Re-Vana Therapeutic

Internal Product Development

EyeLief Implant:
Sustained delivery of established anti-VEGF biologic 4+ months

Strategic Partnerships

External Collaborations

EyeLief and OcuLief Platforms:
Sustained delivery for novel biologic and small molecule drugs
Planned Product Portfolio

**PRODUCT**

**RT1: EyeLief –**
Sustained delivery of anti-VEGF

- 6 Month Tolerability/PK study completed
- Proof of Concept study in progress
- Discussions in progress with API suppliers
- Pre-clinical

**RT2: EyeLief –**
Sustained release small molecule anterior segment drug

- 4-6 Month Proof of Concept 2019
- In vitro

**RT3: OcuLief –**
Sustained delivery of novel compound

- Strategic collaboration Proof of Concept agreement in negotiation
- Ongoing
Financing

Pre-Series A $2M

- Term sheet executed – ExSight Ventures
- Existing investor commitments - $700k
- Planned closing Q3 2019

Use of Proceeds

- Finalize lead API candidate for internal development
- Initiate pre-IND activities
- Expand operations
- Strengthen and expand IP portfolio - existing and new filings
- Execute 1 long-term partnership with world class pharma company
Extensive Experience in Ocular Drug Development & Delivery

Michael O'Rourke
CEO

Prof Clive Wilson
CSO & Scientific Advisor
Europe

Prof. Barry Kuppermann
Scientific Advisor
USA

David Guyer MD
Scientific Advisor
USA

Dr Brian Levy
Scientific Advisor
USA

Mr Jim Sharkey
Retina Physician Director

Prof. Barry Kuppermann
Scientific Advisor
USA

Prof. Barry Kuppermann
Scientific Advisor
USA

Prof. Barry Kuppermann
Scientific Advisor
USA

Prof. Barry Kuppermann
Scientific Advisor
USA

Prof. Barry Kuppermann
Scientific Advisor
USA

Prof. Barry Kuppermann
Scientific Advisor
USA

Prof. Barry Kuppermann
Scientific Advisor
USA
Re-Vana Offers a Major Investment Opportunity

- **Experienced Team**: Extensive global, commercial and development expertise

- **Large Established Ophthalmic Markets**: $19.2B anterior and posterior segment market opportunity (2022)

- **Making Great Drugs Better**: Sustained release platforms for both large and small molecules

- **Novel Technology**: Highly-differentiated photo-crosslinked technologies, Robust IP estate, Strategic partnership milestones achieved

- **Major Competitive Advantages**: > 50% biologic drug loading, Projected 4 months + delivery, Large and small molecule capability, Proven EyeLief™ Tolerability, Customized delivery
Thank You

mor.revana@gmail.com
(1) 813 323 1438